Filing Analysis
Minerva Neurosciences announced a change in its executive accounting leadership. Anthony Aliquo has been promoted to Chief Accounting Officer and principal accounting officer, while Fred Ahlholm will step down as the company's principal accounting officer but remain as CFO.
📋 Key Facts
- Anthony Aliquo appointed as Chief Accounting Officer (CAO) and principal accounting officer effective August 10, 2026.
- Fred Ahlholm ceased serving as principal accounting officer on August 10, 2026, but continues as CFO and principal financial officer.
- Mr. Aliquo's annual base salary increased to $296,696 effective July 1, 2026.
- Mr. Aliquo's annual performance bonus target is set at 35% of his base salary.
- Mr. Aliquo brings over 10 years of accounting experience, including prior roles at BDO USA and Deloitte & Touche.
Minerva Neurosciences, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal notice that a press release containing these results was issued on August 7, 2026.
📋 Key Facts
- Reporting date: August 7, 2026
- Financial period covered: Quarter ended June 30, 2026
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the actual press release with financial data
Minerva Neurosciences reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Stockholders approved amendments to the Certificate of Incorporation regarding officer exculpation and forum provisions, and the Board adopted amended and restated bylaws.
📋 Key Facts
- Stockholders approved the 'Exculpation Amendment' to limit liability of certain officers for monetary damages per Delaware law.
- Stockholders approved the 'Exclusive Forum Amendment' to eliminate the exclusive forum provision.
- The Board approved Amended and Restated Bylaws effective June 3, 2026, which include updates to advance notice procedures and universal proxy rule compliance (Rule 14a-19).
- Two directors, Dr. David Kupfer and Jan van Heek, were elected to the Board until the 2029 annual meeting.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Stockholders voted for a 1-year frequency for advisory votes on executive compensation.
Minerva Neurosciences entered into an 'at-the-market' (ATM) offering agreement with Leerink Partners LLC to sell up to $75 million in common stock. Additionally, the company announced a revision to the relapse assessment phase of its Phase 3 C19 trial for roluperidone, extending it from 40 to 52 weeks following FDA feedback.
🚩 Red Flags
- Potential for significant shareholder dilution via the $75M ATM facility.
- Clinical trial extension (relapse assessment phase) based on FDA feedback, which increases the time to data and potentially increases costs.
📋 Key Facts
- Entered into ATM offering agreement with Leerink Partners LLC on May 27, 2026.
- Maximum aggregate offering price of ATM shares is $75.0 million.
- Agent (Leerink Partners) receives a commission of 3.0% of gross proceeds.
- Phase 3 C19 trial relapse assessment phase extended from 40 weeks to 52 weeks due to FDA feedback.
- Topline efficacy results for C19 trial expected in H2 2027, with relapse assessment data in H2 2028.
Minerva Neurosciences, Inc. reported its financial results for the first fiscal quarter ended March 31, 2026. The filing is a routine quarterly update furnished to the SEC under Item 2.02.
📋 Key Facts
- The report was filed on May 5, 2026, covering the fiscal quarter ended March 31, 2026.
- The company furnished a press release as Exhibit 99.1 regarding its financial results.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
- Minerva Neurosciences is listed on The Nasdaq Capital Market under the ticker NERV.
Minerva Neurosciences announced its 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026. Due to the timing shifting more than 30 days from the prior year's anniversary, the company established new deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting scheduled for June 3, 2026
- Stockholder proposal deadline under Rule 14a-8 set for April 16, 2026
- Director nomination and other business notice deadline set for April 21, 2026
- The meeting date is more than 30 days from the anniversary of the 2025 annual meeting
Minerva Neurosciences announced the resignation of President Geoffrey Race, effective March 31, 2026, and the appointment of James O’Connor as Chief Business Officer and General Counsel. The company entered into a settlement agreement with Mr. Race involving significant severance benefits and a one-year consultancy agreement.
🚩 Red Flags
- Full acceleration of stock option vesting for a departing executive.
- Unusually long extension of the option exercise period until January 1, 2030.
- Immediate transition to a high-rate consultancy role (£333/hour) following resignation.
📋 Key Facts
- Geoffrey Race resigned as President and Director of Mind-NRG SARL effective March 31, 2026.
- Race will receive a one-time payment of his annual salary, 12 months of pension contributions, and a pro-rated 2026 bonus.
- Additional severance includes £30,000, medical/life insurance coverage, and legal fee reimbursement up to £15,000.
- All outstanding stock options for Mr. Race were fully vested as of March 31, 2026, with the exercise period extended to January 1, 2030.
- A consultancy agreement was established with Mr. Race at a rate of £333 per hour for a minimum of 35 hours per month starting April 15, 2026.
- James O’Connor was appointed Chief Business Officer and General Counsel effective April 21, 2026.
Minerva Neurosciences, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to this filing.
📋 Key Facts
- Filing date: March 11, 2026
- Reporting period: Quarter and fiscal year ended December 31, 2025
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- The press release is included as Exhibit 99.1
Minerva Neurosciences held a virtual Key Opinion Leader (KOL) event to provide clinical updates on its roluperidone Phase 3 trial for schizophrenia. The company detailed the trial design, enrollment targets, and expected timelines for topline efficacy results.
🚩 Red Flags
- Forward-looking statements highlight risks regarding cash runway and potential need for additional financing.
- Clinical trial delays or unsatisfactory outcomes are noted as significant risks to the company's objectives.
📋 Key Facts
- Scheduled initiation of confirmatory Phase 3 trial of roluperidone (for negative symptoms in schizophrenia) in Q2 2026.
- Trial design: 380 patients, randomized 1:1 to placebo or 64 mg daily dose of roluperidone.
- Primary efficacy endpoint: Change from baseline in PANSS Marder negative symptoms factor score (NSFS) at 12 weeks.
- Study includes a 40-week relapse assessment phase following the initial 12-week treatment period.
- Topline efficacy results expected in H2 2027; relapse assessment data expected in H2 2028.
Minerva Neurosciences held its 2025 Annual Meeting of Stockholders where shareholders approved several key items, including the election of two directors and a significant increase in authorized common stock. The meeting also resulted in the approval of an amendment to the company's equity incentive plan.
🚩 Red Flags
- Significant increase in authorized share count (doubling from 125M to 250M) suggests potential future dilution.
📋 Key Facts
- Stockholders elected Fouzia Laghrissi-Thode and Inderjit Kaul to the Board of Directors until 2028.
- Shareholders approved increasing total authorized Common Stock from 125,000,000 to 250,000,000 shares (Proposal 2).
- Approved issuance of shares upon conversion of Series A Convertible Voting Preferred Stock to comply with Nasdaq Rule 5635(d) (Proposal 3).
- Approved an amendment to the 2013 Equity Incentive Plan to increase authorized shares by 12,500,000 (Proposal 4).
- Ratified Deloitte & Touche LLP as independent auditors for fiscal year ending Dec 31, 2025 (Proposal 6).
Minerva Neurosciences has appointed Dr. Inderjit Kaul to its Board of Directors, a move triggered by a prior securities purchase agreement with Vivo Capital LLC. In addition to his board role, Dr. Kaul has entered into a consulting agreement that includes significant performance-based equity incentives tied to Phase 3 clinical trial milestones.
🚩 Red Flags
- Related-party transaction: The director is also being paid via a consulting agreement.
- Significant equity incentive (0.7% of total shares) tied directly to clinical trial success, which may create alignment issues or perceived pressure regarding trial reporting.
📋 Key Facts
- Appointed Inderjit Kaul, M.D., MPH as a Class II director on November 14, 2025.
- Appointment follows a Securities Purchase Agreement with Vivo Capital LLC (dated Oct 21, 2025) to increase board size and appoint up to three directors designated by the investor.
- Dr. Kaul receives a $40,000 annual cash retainer (prorated for 2025).
- Initial equity grant of 9,500 shares vesting quarterly over three years.
- Consulting agreement: 25-30 hours/month at $450 per hour for an initial six-month term.
- Performance-based consulting options: Potential to hold up to 0.7% of the Company's Share Total, with vesting tied to Phase 3 clinical trial endpoints (12-week primary endpoint and 40-week safety data).
Minerva Neurosciences entered into a $200 million private placement agreement to issue Series A Convertible Preferred Stock and warrants to accredited investors. The capital is primarily intended to fund the Phase 3 confirmatory trial of roluperidone for schizophrenia.
🚩 Red Flags
- Significant potential dilution: The conversion price of $2.11 is fixed, and the total offering size ($200M) represents a massive increase in share count relative to typical micro-cap structures.
- Milestone-contingent financing: A large portion of the capital ($120M) depends on clinical trial success (Phase 3 primary endpoint), creating high binary risk for investors and company solvency.
- Control shift: Investors are gaining board seats and advisory control, indicating a significant change in corporate governance/control structure.
📋 Key Facts
- Aggregate offering price up to $200 million via Series A Preferred Stock and two tranches of warrants.
- Initial gross proceeds of $80 million from 80,000 shares at $1,000 per share.
- Tranche A Warrants: Up to $80 million in additional proceeds upon achievement of a 'Milestone Event' (Phase 3 primary endpoint for roluperidone).
- Tranche B Warrants: Up to $40 million in additional proceeds via cashless exercise on the Milestone Event or 3-year anniversary.
- Conversion price for Series A Preferred Stock is set at $2.11 per share upon stockholder approval.
- Investors include Vivo Capital LLC, which will gain up to three board seats and influence over a new Scientific Advisory Board (SAB).
- Closing expected on or around October 23, 2025.
Minerva Neurosciences has regained compliance with Nasdaq's Net Income Rule, but the company is now subject to a one-year discretionary panel monitor. During this period, any failure to meet listing requirements will result in immediate delisting proceedings without the opportunity for a compliance plan.
🚩 Red Flags
- One-year discretionary monitoring period by Nasdaq Panel.
- Loss of right to submit a compliance plan if a new deficiency occurs during the monitor period.
- History of non-compliance regarding Market Value and Equity Rules (previously disclosed).
📋 Key Facts
- On March 17, 2025, Nasdaq notified the Company it has regained compliance with Listing Rule 5550(b)(3) (Net Income Rule).
- The Company will be subject to a discretionary panel monitor for one year starting March 17, 2025.
- During the monitoring period, any new deficiency will lead to an immediate Delist Determination Letter without the option to submit a compliance plan.
- Compliance was verified based on the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Minerva Neurosciences received a conditional reprieve from the Nasdaq Hearings Panel regarding its delisting notice. The company must demonstrate compliance with both Market Value of Listed Securities (MVLS) and Stockholders' Equity rules by March 31, 2025.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq Listing Rule 5550(b)(2)
- Requirement to disclose transactions intended to achieve equity compliance (often implies potential reverse split or dilutive financing)
- Uncertainty regarding ability to maintain listing standards
- Need to provide 12-month income projections under pressure from Nasdaq
📋 Key Facts
- Nasdaq Hearings Panel granted a request for continued listing on January 10, 2025.
- Compliance requirement 1: File public disclosure of transactions to achieve compliance with the $2.5 million minimum stockholders' equity rule by March 31, 2025.
- Compliance requirement 2: Provide 12-month income projections with underlying assumptions and evidence of compliance with all Nasdaq listing criteria by March 31, 2025.
- The company previously fell below the $35 million minimum Market Value of Listed Securities (MVLS) for 31 consecutive business days.
Minerva Neurosciences, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on December 5, 2024. The meeting included the election of two directors and advisory votes on executive compensation and auditor ratification.
📋 Key Facts
- Election of Hans Peter Hasler to the Board of Directors (3,384,409 votes 'For').
- Election of Dr. Remy Luthringer to the Board of Directors (3,705,617 votes 'For').
- Stockholders approved Proposal 2 regarding advisory compensation for Named Executive Officers.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Minerva Neurosciences received a second notice from Nasdaq stating its securities will be delisted due to failure to maintain the minimum Market Value of Listed Securities ($35 million). The company intends to request a hearing before a Nasdaq Hearings Panel to seek an extension.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to meet minimum market value requirements (Rule 5550(b)(2))
- Uncertainty regarding the Panel's decision to grant an extension
📋 Key Facts
- Company failed to meet the $35 million minimum Market Value of Listed Securities requirement for 31 consecutive business days.
- The deadline to regain compliance was October 7, 2024.
- Nasdaq staff has determined to delist securities unless a hearing is requested.
- The company intends to timely request a hearing before the Nasdaq Hearings Panel.
- A successful hearing could potentially grant an extension until April 5, 2025.
Minerva Neurosciences, Inc. announced the expected date for its 2024 annual meeting of stockholders and established deadlines for stockholder proposals and director nominations.
📋 Key Facts
- The 2024 Annual Meeting of Stockholders is scheduled for December 5, 2024.
- Stockholders must provide notice of intention to nominate directors or bring business by the close of business on October 1, 2024.
- Stockholder proposals intended for inclusion in the proxy statement (Rule 14a-8) must also be received by October 1, 2024.
Minerva Neurosciences announced the upcoming resignation of Jeryl Hilleman from the Board and her role as Chair of the Audit Committee, effective August 6, 2024. The company has already named successors for her committee roles to ensure continuity.
🚩 Red Flags
- None identified; the filing explicitly states there were no disagreements with management or the Board regarding the departure.
📋 Key Facts
- Jeryl Hilleman will resign from the Board and as Chair of the Audit Committee effective August 6, 2024.
- The resignation is intended to allow Ms. Hilleman to focus on other opportunities.
- Jan van Heek will succeed Ms. Hilleman as Chair of the Audit Committee, effective August 6, 2024.
- Dr. David Kupfer will join the Audit Committee, effective August 6, 2024.
Minerva Neurosciences received a notice from Nasdaq stating it is non-compliant with the Minimum Market Value of Listed Securities (MVLS) requirement. The company has a 180-day grace period to regain compliance by October 7, 2024.
🚩 Red Flags
- Delisting notice from Nasdaq (Listing Rule 5550(b)(2))
- Failure to meet minimum market value requirements indicates significant loss in market capitalization/investor confidence.
- Risk of delisting if compliance is not met by October 7, 2024.
📋 Key Facts
- Received notice from Nasdaq on April 10, 2024.
- Non-compliance is due to the market value of listed securities being below $35,000,000 for the last 31 consecutive business days.
- The company has a grace period until October 7, 2024, to regain compliance.
- To regain compliance, the MVLS must close at $35,000,000 or more for at least 10 consecutive business days.
Minerva Neurosciences received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for roluperidone to treat negative symptoms in schizophrenia patients. This represents a significant regulatory setback for the company's lead drug candidate.
🚩 Red Flags
- FDA Complete Response Letter (CRL) indicates the application will not be approved in its current form, requiring additional data or clinical trials.
📋 Key Facts
- The FDA issued a Complete Response Letter (CRL) on February 27, 2024.
- The CRL pertains to the New Drug Application (NDA) for roluperidone.
- Target indication: treatment of negative symptoms in patients with schizophrenia.